AVE-1625 (CAS 358970-97-5)
QUICK LINKS
The central cannabinoid (CB1) receptor is a G protein-coupled receptor that is widespread in the central nervous system and several peripheral tissues and binds the active component of cannabis, Δ9-tetrahydrocannabinol (1). Signaling through the CB1 receptor is involved in attentional and working memory deficits as well as obesity (2,3,4). AVE-1625 is a selective, highly potent antagonist for the CB1 receptor with Ki values of 0.16-0.44 nM (4). At 1-3 mg/kg, AVE-1625 significantly enhances the performance of rodents in working memory tasks (4). At 30 mg/kg, AVE-1625 reduces caloric intake by more than 50% of controls, reduces hepatic glycogen levels in rodents and significantly increases lipolysis from fat tissues (5).
AVE-1625 (CAS 358970-97-5) References
- A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. | Gómez, R., et al. 2002. J Neurosci. 22: 9612-7. PMID: 12417686
- Cannabinoid receptors as therapeutic targets. | Mackie, K. 2006. Annu Rev Pharmacol Toxicol. 46: 101-22. PMID: 16402900
- CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. | Herling, AW., et al. 2007. Am J Physiol Endocrinol Metab. 293: E826-32. PMID: 17595216
- Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625. | Zuurman, L., et al. 2010. J Psychopharmacol. 24: 363-71. PMID: 18801827
- Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. | Janero, DR. and Makriyannis, A. 2009. Expert Opin Emerg Drugs. 14: 43-65. PMID: 19249987
- Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625. | Liebig, M., et al. 2010. Obesity (Silver Spring). 18: 1952-8. PMID: 20168311
- Ligand Binding Sensitivity of the Extracellular Loop Two of the Cannabinoid Receptor 1. | Bertalovitz, AC., et al. 2010. Drug Dev Res. 71: 404-411. PMID: 21170298
- AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. | Black, MD., et al. 2011. Psychopharmacology (Berl). 215: 149-63. PMID: 21181124
- Pharmacokinetic/pharmaco-dynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on Δ(9)-tetrahydrocannabinol challenge tests. | Guan, Z., et al. 2016. Br J Clin Pharmacol. 81: 713-23. PMID: 26617196
- Characterization of CB1 cannabinoid receptors using receptor peptide fragments and site-directed antibodies. | Howlett, AC., et al. 1998. Mol Pharmacol. 53: 504-10. PMID: 9495818
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AVE-1625, 1 mg | sc-221277 | 1 mg | $64.00 | |||
AVE-1625, 5 mg | sc-221277A | 5 mg | $288.00 |